September 24, 2026
Houston, TX – September 24, 2026 – Vivifi Medical, a medical device company developing a minimally invasive, function-preserving treatment for benign prostatic hyperplasia (BPH), has been named to Pepperdine Graziadio Business School's ninth annual Most Fundable Companies® List. Selected from more than 2,100 applicants representing all 50 states, Vivifi is one of 14 companies recognized this year for its investment readiness and its potential to transform its market.
Applicants are evaluated on financial projections, market opportunity, competitive positioning, intellectual property, and management strength. Submissions are reviewed by investors, venture advisors, and Pepperdine faculty. The 2026 winners were recognized at the Most Fundable Companies® Showcase on September 23 at Pepperdine's Villa Graziadio Executive Center in Malibu, CA. Dan Root, Vivifi's Head of Medical Affairs, represented the company at the showcase. The showcase was presented by the Singleton Foundation for Financial Literacy and Entrepreneurship.
BPH affects more than 660 million men worldwide. Today's procedures act on the enlarged gland itself, which forces patients to trade symptom relief for sexual and urinary side effects, and many patients need retreatment. Vivifi targets the cause instead. Its non-surgical, non-urethral approach selectively closes the venous pathway that delivers testosterone-rich blood to the prostate. The approach is designed to let the gland regress naturally, without incisions or implants.
The recognition follows Vivifi's selection in May to the MedTech Innovator 2026 Accelerator Cohort, one of 65 companies chosen from more than 1,800 global applicants, and its inclusion on the inaugural MTI Index.
"Most Fundable Companies applies the same lens investors use in diligence: market, IP, financials, and team. Being selected from more than 2,100 companies validates the fundamentals behind our root-cause approach to BPH. Our focus now is advancing the clinical program and closing our Series A to advance this treatment towards patients." - Tushar Sharma, CEO of Vivifi Medical
As a list winner, Vivifi Medical is profiled on Entrepreneur.com and will be featured in the November/December print issue of Entrepreneur magazine. View the full list of 2026 winners here and watch the showcase replay here.
About Vivifi Medical
Vivifi Medical is a Houston-based medical device company developing a minimally invasive, function-preserving treatment* for benign prostatic hyperplasia (BPH). Founded to make BPH care simpler and more humane, Vivifi combines expertise in urology, vascular medicine, and device design to create solutions that respect patient anatomy and quality of life. The company is headquartered in Houston, TX with an office in Portland, OR, and is currently in clinical investigation to evaluate the safety and effectiveness of its technology. Vivifi is committed to partnering with clinicians and investors who share its vision of better outcomes and faster recovery for men with BPH.
About Pepperdine Most Fundable Companies®
The Most Fundable Companies® List is an annual program hosted by Pepperdine Graziadio Business School to promote startup business development, provide pathways for funding, and inspire entrepreneurial spirit nationwide. The program launched in 2018 and is a free resource that helps entrepreneurs assess their readiness for private investment. It uses a multi-phase assessment of financial projections, market opportunity, intellectual property, competitive advantage, and management team strength.
Disclaimer: The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It does not constitute investment advice, nor is it an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.
Media Contact:
Tushar Sharma
CEO, Vivifi Medical
info@vivifimedical.com
2450 Holcombe Blvd, Ste 1420, Houston, TX 77021* NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
